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Background: A new, simple and accurate stability-indicating reverse phase high performance liquid chromatography
method was developed and validated during the early stage of drug development of an oral lyophilizate dosage form
of cetirizine dihydrochloride.
Methods: For RP-HPLC analysis it was used an Eclipse XDB C8 column 150 mm × 4.6 mm, 5 μm (Agilent columns,
Barcelona, Spain) as the stationary phase with a mobile phase consisted of a mixture of 0.2 M K2HPO4 pH 7.00
and acetonitrile (65:35, v/v) at a flow rate of 1 mL min −1. Detection was performed at 230 nm using diode array
detector. The method was validated in accordance with ICH guidelines with respect to linearity, accuracy, precision,
specificity, limit of detection and quantification.
Results: The method results in excellent separation between the drug substance and its stress-induced degradation
products. The peak purity factor is >950 for the drug substance after all types of stress, which confirms the complete
separation of the drug substance peak from its stress induced degradation products.
Regression analysis showed r2 > 0.999 for cetirizine dihydrochloride in the concentration range of 650 μg mL −1 to
350 μg mL−1 for drug substance assay and a r2 > 0.999 in the concentration range of 0.25 μg mL−1 to 5 μg mL−1 for
degradation products. The method presents a limit of detection of 0.056 μg mL −1 and a limit of quantification of
0.25 μg mL−1. The obtained results for precision and accuracy for drug substance and degradation products are within
the specifications established for the validation of the method.
Conclusions: The proposed stability-indicating method developed in the early phase of drug development
proved to be a simple, sensitive, accurate, precise, reproducible and therefore useful for the following stages of
the cetirizine dihydrochloride oral lyophilizate dosage form development.Background
In the early stage of drug development, forced degrad-
ation studies are used to facilitate the development of
an analytical methodology, in order to obtain a better
understanding of the drug substance (DS) studied and
the final drug product (DP) stability, providing data
regarding degradation pathways and degradation prod-
ucts (DE) [1]. Such studies are needed to assure that all* Correspondence: pflorezb@gmail.com
†Equal contributors
1Pharmacy and Pharmaceutical Technology Department, Faculty of
Pharmacy, University of Barcelona, Avda Joan XXIII s/n 08028, Barcelona,
Spain
2Reig Jofre Group, c. Gran Capitá 6 08970, Sant Joan Despi, Barcelona, Spain
© 2014 Flórez Borges et al.; licensee BioMed C
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.the regulatory requirements of a drug are fulfilled, such
as the identification of possible DE, degradation path-
ways and intrinsic stability of the drug molecule. Part
of the study is the development and validation of the
stability indicating analytical method involved [2,3].
The overall objective of this work is to develop a new
formulation with the drug substance (C21H27Cl3N2O3)
cetirizine dihydrocloride (CTZ; the dihydrochloride of a
2-[4-chlorobenzhydryl) piperazin-1-yl] ethoxyacetic acid).
CTZ is a non-sedative H1 antihistaminic drug, a pipera-
zine derivative and metabolite of hydroxyzine (Figure 1)
[4]. CTZ presents an increased degree of polarity, which
makes it less capable of crossing the blood brain barrier,
hence reducing the sedative side effects in comparisonentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Chemical structure of cetirizine dihydrochloride. Ph. Eur. 7th Edition 2014 (8.0).
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mine and hydroxyzine [5-7]. CTZ is administrated gener-
ally in tablets and liquid forms orally to promote the relief
of symptoms related to allergic rhinitis, chronic idiopathic
urticaria and other rashes [8,9].
This new formulation consists of an oral lyophilized
dosage form, whose aim is to facilitate swallowing (in
the case of patients with dysphagia, such as children and
elderly, for instance), easy to administer, effective, safe
and stable over time.
Several HPLC methods have been reported in litera-
ture for the determination of CTZ alone [10-13] and
also determining CTZ simultaneously with other drug
substances, as in multicomponents preparations [14-16].
In order to develop a new chromatographic method for
the determination and quantification of CTZ and its DE
generated after a forced degradation study, several chro-
matographic methods for CTZ were investigated in the
literature. Among them, was the Ph. Eur. method for
CTZ [17]. However, the latter was discarded due to the
use of a normal phase chromatographic column and mo-
bile phase that used much organic solvent (acetonitrile,
not very cost-effective). Also, the Ph. Eur. method pre-
sents a very acid mobile phase pH (pH <0.5), which is
known to diminish the life span of the chromatographic
column [18]. Also, some chromatographic analytical
methods [12,13] used chromatographic columns of re-
verse phase, usually C18 and C8. Depending on the type
of separation pursued (as for instance, CTZ combined
with another DS), isocratic or gradient methods were
used, and also mobile phases with ionic pairing. We have
developed a reverse-phase high performance liquid chro-
matography (RP-HPLC) method by studying the effect
of the stationary phase (C18 or C8 analytical columns)
on peak resolution, the influence of pH -mobile phase-
when adjusting the desired retention time (tR) for the
DS. Plus, by using a reverse-phase column, we reduced
the amount of organic solvent (acetonitrile) used for theidentification of the DS, in comparison to the analytical
method validated by Ph. Eur. [17], which uses a normal
phase chromatographic column, requiring more organic
solvent due to its characteristics [18-25]. Therefore the
aim of this study is to determine all possible DE generated
under stress conditions, by developing and validating a
stability-indicating RP-HPLC method for cetirizine dihy-
drochloride in the early stage of drug development of an
oral lyophilizate.
Methods
Chemicals and reagents
All chemicals were analytical grade and used as re-
ceived. All solutions were prepared in Milli-Q deionized
water from a Milli Q gradient A10 water purification sys-
tem (Molsheim, France). CTZ bulk powder (Cetirizine
dihydrochloride, Ph. Eur) was purchased from Jubilant
Lifesciences Ltd (Mysore, India) and kindly provided by
Reig Jofre Group (Barcelona, Spain). HPLC grade aceto-
nitrile was obtained from Panreac (Barcelona, Spain).
Ortho-phosphoric acid 85% was purchased from Panreac
(Barcelona, Spain). Potassium phosphate dibasic Ph. Eur.
(K2HPO4) was purchased from Fagron (Terrassa, Spain).
Hydrochloric acid 37%, sodium hydroxide and hydrogen
peroxide (H2O2) at 33% were purchased from Panreac
(Barcelona, Spain).
Equipment and chromatographic conditions
Samples were analyzed on Dionex Ultimate 3000 HPLC
Thermo Fisher Scientific (California, USA), equipped with
data system Chromeleon version 6.8 SP2 Build 2284, with
degasifier SR3000, LPG-3400 quaternary pump, injector
WPS3000, oven 6P TCC-3100, UV–vis detector PDA-
3000. For initial development studies it was used an
analytical chromatographic column Kromasyl 100-5C18
150 mm × 4.6 mm, 5 μm particle size (Tecnokroma
Akzonobel, Terrasa, Spain). For final development and
method validation, it was used an analytical
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4.6 mm, 5 μm particle size (Agilent columns, Barce-
lona, Spain). An isocratic mobile phase consisting of
acetonitrile and 0.2 M potassium phosphate dibasic Ph.
Eur. buffer solution at pH 7.00 (35:65 v/v) was used,
and the analysis was carried out at a flow rate of
1 mL min −1. All determinations were performed at 30°C.
The injection volume was 25 μL. The detector was set at λ
230 nm. The peak homogeneity was expressed in terms of
peak purity factor and was obtained directly from spectral
analysis report using the above mentioned software.
Other apparatus included a Crison micropH 2002 pHFigure 2 SPARC speciation plot for cetirizine dihydrochloride. Anionizmeter (Barcelona, Spain) and Heraeus oven T5028 for
thermal degradation (dry heat at 105°C) (Hanaus,
Germany).Forced degradation studies and preparation of samples
The forced degradation studies were carried out by prepar-
ing several standard solutions of CTZ at 500 μg mL−1, for
each degradation study. Each sample was analyzed accord-
ing to the previous procedures described under the pro-
posed analytical method. In order to determine whether
the analytical method is suitable to be a stability-indicatinged (S1) and protonized (S6) species.
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were carried out according to the following procedure:
a) Acid and basic hydrolysis: 5 mg of bulk powder was
treated with 5 mL of 0.1 M HCl and 0.1 M NaOH.
The flasks were placed in a dry air oven at 105°C.
Another 5 mg of bulk powder was also treated with
5 mL of 0.1 M HCl and 0.1 M NaOH at room
temperature, for 24 hours.
b) Oxidation with H2O2 at 33%: 5 mg of bulk powder
was exposed to 5 mL of hydrogen peroxide at 33%
(W/v). The vial was kept at room temperature for
24 hours.
c) Infrared (IR) and Ultraviolet (UV) light: 5 mg of
bulk powder was exposed under an infrared lamp
and another 5 mg of bulk powder was exposed
under an ultraviolet lamp, for 24 hours.
d) Humidity HR 79%: the 5 mg bulk powder sample
was placed inside a humidifier with HR 79%, for
24 hours.
e) Heat at 105°C: 5 mg of bulk powder sample was
placed inside a 105°C dry air oven for 24 hours.
f ) Shed sunlight for 15 days: 5 mg of bulk powder was
kept in a vial for 15 days, at room temperature and
exposed to direct sunlight.
Once the stress conditions were complete, 10 mL of
0.2 M phosphate buffer (pH 7.00) was added to the sam-
ples in order to achieve the standard solution concentra-
tion of 500 μm mL-1. Moreover, all the solutions and
blanks were filtered with a 0.45 μm syringe filtration disk0,0 10,0 20,0 30
-100
125
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900 DEGRADACIONMP0709 #11 [modif ied by ULTIMATE 3000]
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Figure 3 Cetirizine dihydrochloride under normal conditions.PVDF. Results were compiled in terms of relative reten-
tion times (rtR) found during the analysis.
Validation of the analytical method
In order to validate the RP-HPLC method developed,
ICHQ2B guideline recommendations were followed, in
terms of selectivity, linearity, range, accuracy, precision,
limit of detection (LOD) and limit of quantification (LOQ)
[26]. In order to fulfill ICH specifications in terms of linear-
ity and range for the analytical method (content uniformity
and assay of DS and finished product), a linear range within
70-130% was studied, by analyzing a series of three replicates,
i.e., three independent sets (k = 3), each with seven different
concentrations (n = 6): 350 μg ml −1 - 650 μg ml −1, consid-
ering 500 μg ml −1 as 100% (standard solution), in order to
provide information on the variation in peak area values
between samples of the same concentration. For evaluation
of the precision estimates, repeatability and intermediate
precision were performed at three concentration levels
(650, 500 and 350 μg ml −1, corresponding to 130, 100 and
70%), and 10 injections of each sample (K = 10), per day.
Mean average, standard deviation (SD) and relative stand-
ard deviation (RSD) of tR and the peak area achieved indi-
vidually of day 1 and 2 were calculated. After the HPLC
analysis, the response factor (RF) was calculated between
the response (Y) and concentration achieved (X), as Y/X.
Therefore, mean average, SD and RSD were calculated
using the response factors obtained with an Excel 2007
spread sheet. The response factors results must comply
with a RSD ± 2%. For accuracy the concentration found
expressed by function of repeatability of the standard,0 40,0 50,0 60,0
UV_VIS_1
min
WVL:230 nm
Table 1 Summary of product degradation peaks in relative retention time (rtR)
Stress conditions rtR (min) CTZ
Humidity HR79% 1.00
Acid hydrolysis *RT 0.51 0.81 0.87 1.00
Acid hydrolysis at 105°C 0.46 0.50 0.64 0.87 1.00 5.00
Ultraviolet light (UV) 0.52 0.59 0.81 1.00 2.00 4.30
Infrared light (IR) 0.51 0.60 0.66 0.81 1.00
Basic hydrolysis *RT 0.53 0.81 0.87 1.00
Basic hydrolysis at 105°C 0.46 0.48 0.51 0.58 0.71 0.86 1.00 1.60 2.00 2.80 3.40 5.00 9.10
Dry heat at 105°C 0.50 0.72 0.80 0.90 1.00 4.30 5.00
Shed sunlight 15 days 0.60 1.00
H2O2 at 33% 0.51 1.00 1.90 2.60 4.40 5.70
Normal conditions 1.00
*RT: Room temperature.
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recovery, with mean average, SD and RSD deviation of
each of the three concentrations studied (650, 500 and
350 μg ml −1, was considered of three replicates) were cal-
culated. For the DS, 98-102% percentage of recovery was
considered as being acceptable [27].
For the determination and quantification of the DE,
linearity, precision, accuracy and LOD and LOQ were
calculated. In order to carry out this validation, further
dilutions from a stock solution of 500 μg ml −1 with the
specified mobile phase were carried out in order to
achieve the correspondent concentrations: 5 μg mL−1,
2.5 μg mL −1, 1.25 μg mL −1, 0.5 μg mL−1, 0.25 μg mL−1,
0.125 μg mL −1. A total of seven independent calibration
curves, i.e., seven replicates ( k = 7) were prepared. The
LOD and LOQ were calculated by the ratio between
the standard deviation of y-intercepts of regression lines
of the seven calibration curves mentioned before by aver-
aging the slopes of calibration curve multiplied by 3.3 andTable 2 Peak purity determination by diode-array UV–vis spe
Forced degradation conditions aPeak purity index match
Humidity HR79% 952
Acid hydrolysis *RT 990
Acid hydrolysis at 105°C 998
Ultraviolet light (UV) 962
Infrared light (IR) 962
Basic hydrolysis *RT 972
Basic hydrolysis at 105°C 986
Dry heat at 105°C 953
Shed sunlight 15 days 996
Oxidative medium *RT 998
CTZ (phosphate buffer solution) 990
aindicates the value for peak purity index match of CTZ above 950, considering 10010, respectively [26,27]. Each serial dilution (k = 7) was an-
alyzed, with n = 6 (level of concentrations).
In terms of relative error and percentage of recovery
three concentrations (5, 1.25 and 0.25 μg mL−1) from
the range of DE were evaluated. All the solutions pre-
pared were filtered with a 0.45 μm syringe filtration disk
PVDF to the vials for injection in the HPLC system.
Results and discussion
HPLC method development
As an early stage study of drug development, our goal
was to acknowledge all possible DE generated under
stress conditions for CTZ. The information acquired in
the early stage of the study will lead us to a better under-
standing of the DS itself and also the possible DE that
we may find during the next step of the oral lyophilized
development study. Therefore it was not our objective
the development of a fast analytical method for the DS
per se, but actually the development of an analyticalctra of CTZ and stress studies results
Decomposition (%) Extent of decomposition
0 None
0 None
19 Substantial
9 Substantial
8 Substantial
0 None
15 Substantial
3 Substantial
10 Substantial
79 Substantial
0 Normal conditions
0 as 100% match; *RT: Room temperature.
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Figure 4 Cetirizine dihydrochloride under humidity HR79%.
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this DS, leaving for the following studies of drug devel-
opment the aim of reducing run time, for instance.
CTZ is freely soluble in water, and practically insoluble
in acetone and metilen chlorate [17]. Considering its
hydrophilic nature, reverse phase columns were chosen
in order to investigate the chromatographic profile with
two types of packing material for stationary phases: C18
(more hydrophobic, octadecylsilyl), and C8 (intermediate
hydrophobicity, octylsilyl). We also studied the molecule0,0 10,0 20,0 3
-5
500
1.000
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2.000
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3.000 DEGRADACIONMP0620 #18 [modified by ULTIMATE 3000]
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Figure 5 Cetirizine dihydrochloride under H2O2 at 33%.of CTZ using the physicochemical calculator SPARC
(Sparc Performs Automated Reasoning in Chemistry)
developed by the United States Environmental Protec-
tion Agency (EPA) for the purpose of predicting which
pH would suit best for CTZ ionization [28]. The speci-
ation plot for CTZ (Figure 2) shows that pH3 is not rec-
ommended for the ionization of CTZ due to the
existence of six different species of ionized CTZ with no
clear definition among them, whereas at pH2 we can
find the protonated CTZ (S6) and at pH7 the anionized0,0 40,0 50,0 60,0
UV_VIS_1
min53 6 - 33,990
WVL:230 nm
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c) f)
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Figure 6 Chromatographic spectra of cetirizine dihydrochloride (b) and its degradation products (a, c, d, e and f) under H2O2
at 33%, in nm.
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Table 3 Repeatability and intermediate precision according to retention time (tR) and peak area for CTZ assay
tR Peak area
Day μg mL−1 Mean average ± aSD (min) bK = 10 cRSD (%) Mean average ± aSD (mAU.min) bK = 10 cRSD (%)
1 650 5.79 ± 0.0274 0.4747 512.54 ± 1.7865 0.5365
500 5.79 ± 0.0327 0.5646 399.69 ± 1.9090 0.4777
350 5.80 ± 0.0228 0.3929 281.21 ± 1.7867 0.6353
2 650 5.77 ± 0.0195 0.3384 511.75 ± 2.2059 0.4310
500 5.78 ± 0.0149 0.2584 399.54 ± 1.5972 0.3997
350 5.80 ± 0.0248 0.4279 281.63 ± 1.0483 0.3722
aSD (Standard deviation); bK (number of injections); cRSD (Relative standard deviation).
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are: 2.7 (pKa1), 3.6 (pKa2) and 7.6 (pKa 3) [29]. How-
ever, due to the finding of chromatographic methods
that used buffer solutions at pH3 or around 3 (2.8, 3.5,
for instance) we decided to considered pH3 in our study
[10-12,14]. During the preliminary studies of the analyt-
ical method development, we have combined different
proportions of acetonitrile and aqueous solution at pH3
(MilliQ water acidified at pH3 with orto-phosphoric acid
85%). The preliminary studies were carried out by the
injection of a 500 μg mL −1 solution of CTZ, using a
C18 analytical chromatographic column, flow rate of
mobile phase of 1 mL min −1, an injection volume of
25 μL, oven temperature of 30°C, 230 nm of wavelength,
in isocratic mode. The effects of the optimum eluent
composition were studied, obtaining a retention time
(tR) of eight minutes for CTZ with a 35:65 (v/v) of aceto-
nitrile and aqueous solution at pH3. Also, we tried to
adjust the mobile phase –studying the effect of the pro-
portion between the organic solvent and buffer solution
pH– in order to achieve a tR of approximately 6–7 for
CTZ. To diminish the tR, we finally tried to use a buffer
solution of 0.2 M K2HPO4 pH7. We observed that main-
taining the same proportions of organic solvent and buf-
fer solution, but changing the pH from 3 to 7, using
potassium phosphate dibasic buffer solution at 0.2 MTable 4 Concentrations found, relative error in percentage, p
aTheoretical
concentration
(μg mL −1)
Concentration
found (μg mL−1)
Relative error%
650 641.29 1.25
650 641.27 1.36
650 640.67 1.45
500 500.96 0.19
500 500.71 0.14
500 505.80 1.14
350 352.16 0.61
350 352.77 0.78
350 355.05 1.42
a650 μg mL−1 = 130%, 500 μg mL−1 = 100%, 350 μg mL−1 = 70%; brecovery limits (98solution at pH7, we achieved a tR of 5–6 minutes. How-
ever, CTZ peak shape presented tail broadening. There-
fore, in order to avoid using ion pair to improve peak
resolution, we have changed the analytical chromato-
graphic column C18 (Kromasyl 100–5 C18) to a C8
(Eclipse XDB C8), and tested with the same conditions
as before: acetonitrile and phosphate buffer solution
pH 7 (35:65, respectively), injection volume 25 μL, flow
rate 1 mL min −1, temperature 30°C, 230 nm of wave-
length. This resulted in eliminating tail broadening. Hav-
ing determined the eluent proportions of the isocratic
mobile phase and the pH of the aqueous solution as
pH7, obtaining the desired tR, we have established the
stability-indicating method to carry out the forced deg-
radation studies.
Results of forced degradation study
CTZ was degraded up to 19% under acid hydrolysis at
105°C, presenting five degradation peaks. Under basic
hydrolysis at 105°C, CTZ was degraded up to 15%, pre-
senting twelve degradation peaks, followed by shed sun
light (10%, one degradation peak), UV (9%, four degrad-
ation peaks), IR (8%, four degradation peaks) and dry
heat at 105°C (3%, 6 degradation peaks). CTZ under
photolytic stress -shed sunlight during 15 days, IR and
UV light- presented degradation peaks with two, fourercentage of recovery and estimates for CTZ assay
bRecovery% Mean recovery cSD of recovery
98.75 98.66 0.09
98.65
98.56
100.19 100.49 0.57
100.14
101.16
100.61 100.95 0.43
100.79
101.44
-102%); cSD (Standard deviation).
Table 5 Mean average, standard deviation (SD) and
relative standard deviation (RSD%) of peak area mAU
(5 – 0.125 μ mL−1)
Theoretical
concentration (μg mL−1)
Mean concentration average ± a
SD (μg mL−1) (b k = 7)
cRSD (%)
5.000 4.0495 ± 0.1040 2.5701
2.500 2.0121 ± 0.0251 1.2502
1.250 1.0012 ± 0.0326 3.2622
0.500 0.4021 ± 0.0327 8.1334
0.250 0.1818 ± 0.0111 6.1605
aSD (Standard deviation); bk (number of replicates); cRSD (relative standard
deviation).
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peaks under acid (three DE peaks) and basic hydrolysis
at room temperature (three DE peaks). However, degrad-
ation was not substantial in both cases (Table 2). Com-
paring the chromatographic profile of CTZ dissolved in
buffer solution (Figure 3) with no stress conditions
(normal conditions) with CTZ under Humidity HR79%
(Figure 4), it is observed that CTZ showed no substan-
tial degradation under Humidity HR79%, presenting a
similar chromatographic profile with CTZ dissolved in
buffer solution at the same concentration. Under oxida-
tive stress, CTZ presented 79% of degradation, showing
five degradation peaks (Figure 5) and in Figure 6 it can
be visualized by the chromatographic spectra of each
DE and CTZ. Furthermore, the peak purity value for
CTZ under oxidative stress was of 998 (considering
1000 as 100% match), indicating a homogenous peak
(Table 2). However, in the beginning of the elution
process, the diode-array assay detects DE higher that
its threshold, demonstrating a possible saturation of the
chromatographic column with H2O2 at 33%. There is
also the hypothesis that 79% of decomposition can also
be the result of the degradation of DE, which would
generate more DE, due to the exposure of CTZ during
24 hours under oxidative condition. This leads to the
conclusion that may be necessary to change the oxida-
tive stress condition procedure, by reducing the con-
centration of peroxide (33%) or reducing the time of
exposure of the DS with H2O2 (24 hours), or both. Sat-
isfactory results were obtained studying the peak purityTable 6 Relative error (%) and percentage of recovery
Concentration
(μg mL −1)
Mean
concentration
found (μg mL−1)
( ak = 7)
bRelative
error%
(mean)
cMean
Recovery%
dSD of
recovery%
5 5.000 0.620 100.070 0.74
1.25 1.248 3.310 99.840 4.10
0.25 0.235 9.390 94.210 10.00
ak = 7 (number of replicates); bmean relative error% ; cmean recovery%;
dstandard deviation.index for CTZ under stress conditions, which confirms
the high specificity of the analytical method for CTZ
(Table 2).
Method validation
The developed method was validated using ICH guide-
lines [26]. Validation parameters included linearity, preci-
sion, accuracy, precision, and specificity, LOD and LOQ
[26,27].
Assay for drug substance method
Linearity for CTZ assay was verified by triplicate analysis
of seven different concentrations, i.e., three sets of 130-
70% range of CTZ. As a result, the linear regression
equation was found to be Y = 769.56 X + 14.573 (r2 =
0.9994, k = 3 (number of replicates), n = 7 (level of con-
centrations), 650 μg mL −1 to 350 μg mL −1) for CTZ. In
which, Y was the dependent variable, X was independent
variable, 769.56 was the slope and which showed change
in dependent (Y) variable per unit change in independ-
ent (X) variable; 14.573 was the Y-intercept i.e., the value
of Y variable when X = 0.
As for the analytical method precision (Table 3), three
concentration levels (650, 500 and 350 μg ml −1, corre-
sponding to 130, 100 and 70%), and 10 injections of each
sample, per day were prepared. The results have shown
the repeatability and intermediate precision presenting a
RSD inferior to 2.7% according to AOAC [27] (1.43% and
1.03%, respectively). In terms of accuracy, according to the
obtained results (Table 4), the percentage of recovery
ranges from 98.56 to 101.44, from being within the limits
established according to AOAC [27] (98-102%), which in-
dicates the accuracy of the method for CTZ.
It was studied seven independent sets of dilutions, i.e.,
seven replicates (k =7), each set with six different concen-
trations (n = 6) in the range of 5–0.125 μg mL−1. Calculat-
ing LOD and LOQ by the ratio between the SD of
y-intercepts of regression lines of the seven serial dilutions
of six different concentrations mentioned before by aver-
aging the slopes of calibration curve multiplied by 3.3 and
10, respectively, the analytical method presented a LOD of
0.056 μg mL−1 and a LOQ of 0.17 μg mL −1. However, it
was demonstrated that the LOQ value of 0.17 μg mL −1
was not lineal. Therefore, taken into account the range de-
fined in ICH guidelines to the DE, for linearity reasons it
was considered the range around a suggested (probable)
limit [26]. Therefore, the linearity should be established
from the LOQ to 120%. So a new LOQ (SD (μg mL −1) =
0.0111, RSD (%) = 6.1605) was established (0.25 μg mL −1).
The linear regression equation was found to be Y =
0.8125X-0.014 (r2 = 0.9999, n = 5 (level of concentrations),
k = 7 (number of replicates), 0.25-5 μg mL−1) (Table 5).
In reference to the results of the analytical method val-
idation, in both Table 5 (repeatability) and Table 6
Flórez Borges et al. DARU Journal of Pharmaceutical Sciences  (2014) 22:82 Page 10 of 11(recovery), the RSD and the range complies with RSD
permitted (2.7%) and the range (90-110%) according to
AOAC [27], assuring the applicability of the developed
analytical method for the determination and quantifica-
tion of DE.
Conclusions
A new and simple RP-HPLC method was developed for
the determination of CTZ and its DE during the early
stage of drug development of an oral lyophilized dosage
form. The proposed method was demonstrated to be lin-
ear, precise, accurate and specific, based on method val-
idation. Satisfactory results were obtained in separating
the peak of CTZ from the DE produced by forced deg-
radation. Plus, it is a cost-effective method that requires
a simple mobile phase (phosphate buffer solution and
acetonitrile, 65:35 v/v) and also does not require the use
of ion pairing, which can result in difficulty in recover-
ing initial column properties. It was also able to separate
with good specificity the DS peak from the entire DE
generated during the stress condition study, which help
us in the next step of the drug development of the oral
lyophilizate, by adapting the validated method consider-
ing further aspects, such as the interactions between
CTZ and the excipients chosen for the final medicinal
product. The proposed analytical method proved to be
stability-indicating and therefore useful in the following
stages of drug development.
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